Clinical Trials » Stargardt Disease
Cell-Based Treatment for Stargardt Disease: Advanced Cell Technology (ACT)
|
RECRUITING Description: ACT has launched a Phase I/II clinical trial of transplanted retinal pigment epithelial (RPE) cells for the treatment of Stargardt disease. The RPE cells are derived from human stem cells. RPE are the first cells affected in people with Stargardt disease. They play a critical role in maintaining the health and function of photoreceptors. The study, taking place at Oregon Health and Science University and the Jules Stein Eye Institute (UCLA), will enroll up to 12 participants. The primary goal of the study is to demonstrate safety and tolerability. The Foundation funded many of the preclinical studies that made this human trial possible. Trial status: Recruiting participants. Partial List of Participation Criteria:
James Bainbridge, M.A., M.B., B.Chir., Ph.D., FRCOpth This e-mail address is being protected from spambots. You need JavaScript enabled to view it Phone: 44 (0) 20 7608 6823 Heather Kneale This e-mail address is being protected from spambots. You need JavaScript enabled to view it Phone: 44(0) 207 608 4023 Moorfields Eye Hospital London, United Kingdom Grampian University Hospitals NHS Trust, Foresterhill, Aberdeen Royal Infirmary Eye Unit Aberdeen, United Kingdom Contact: Vikki McBain 01224 552543 Jules Stein Eye Institute, UCLA School of Medicine Los Angeles, California Contact: Logan Hitchcock 310-825-3046 Wills Eye Institute-Mid Atlantic Retina Philadelphia, Pennsylvania Contact: Shellie Markun This e-mail address is being protected from spambots. You need JavaScript enabled to view it Articles: Clinical Trial Underway for Stem Cell Treatment Additional Information: Listing of ACT’s Stargardt disease stem cell treatment on ClinicalTrials.gov |
